Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer

Dong,Wenjie; Li,Na; Pei,Xiufeng; Wu,Xinai

doi:10.3892/ol.2018.7881

Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer

Authors:
- Wenjie Dong
- Na Li
- Xiufeng Pei
- Xinai Wu
View Affiliations

Affiliations: Department of Internal Medicine‑Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Internal Medical Oncology, Tumor Hospital of Baotou, Baotou, Inner Mongolia 014030, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/ol.2018.7881
Pages: 4207-4214
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dual-specificity phosphatase-2 (DUSP2), a negative regulator of extracellular‑regulated kinase activity, has been identified as an important kinase with emerging roles in cancer. However, the clinical significance of DUSP2 in colorectal cancer (CRC) remains to be fully elucidated. In the present study, the expression of DUSP2 was investigated using immunohistochemistry in 96 patients with CRC. Cell viability was estimated using a cell counting kit‑8 assay, and cell apoptosis by flow cytometry. The relationship between DUSP2 expression and patient characteristics, including overall survival, were studied retrospectively in these patients. It was found that DUSP2 was differentially expressed between left‑sided colon carcinoma (LSCC) and right‑sided colon carcinoma (RSCC). It was also found that decreased expression of DUSP2 was correlated with significantly shorter overall survival (P=0.001) and short distant-metastasis-free survival (P=0.002). In univariate comparisons, the decreased expression of DUSP2 was found to be an independent risk factor for poor survival rate (HR 3.55, CI 1.092‑9.896; P=0.002). It was also found that the enforced overexpression of DUSP2 sensitized CRC cells to cetuximab. In conclusion, the findings demonstrated that DUSP2 was differentially expressed between RSCC and LSCC, and that the overexpression of DUSP2 increased the inhibitory effect of cetuximab in CRC, suggesting that DUSP2 may be a novel biomarker and therapeutic target in CRC therapy.

View Figures

View References

1	Bermudez O, Pages G and Gimond C: The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. Am J Physiol Cell Physiol. 299:C189–C202. 2010. View Article : Google Scholar : PubMed/NCBI
2	Wei W, Jiao Y, Postlethwaite A, Stuart JM, Wang Y, Sun D and Gu W: Dual-specificity phosphatases 2: Surprising positive effect at the molecular level and a potential biomarker of diseases. Genes Immun. 14:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hamamura K, Nishimura A, Chen A, Takigawa S, Sudo A and Yokota H: Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Cellular signalling. 27:828–835. 2015. View Article : Google Scholar : PubMed/NCBI
4	Perander M, Al-Mahdi R, Jensen TC, Nunn JA, Kildalsen H, Johansen B, Gabrielsen M, Keyse SM and Seternes OM: Regulation of atypical MAP kinases ERK3 and ERK4 by the phosphatase DUSP2. Sci Rep. 7:434712017. View Article : Google Scholar : PubMed/NCBI
5	Yin Y, Liu YX, Jin YJ, Hall EJ and Barrett JC: PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 422:527–531. 2003. View Article : Google Scholar : PubMed/NCBI
6	Haag T, Richter AM, Schneider MB, Jimenez AP and Dammann RH: The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms. BMC Cancer. 16:492016. View Article : Google Scholar : PubMed/NCBI
7	Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, Lin SC and Tsai SJ: Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest. 121:1905–1916. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lee YH, Morrison BL and Bottaro DP: Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 289:20448–20461. 2014. View Article : Google Scholar : PubMed/NCBI
9	Karakashev SV and Reginato MJ: Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget. 6:1967–1980. 2015. View Article : Google Scholar : PubMed/NCBI
10	Hou PC, Li YH, Lin SC, Lin SC, Lee JC, Lin BW, Liou JP, Chang JY, Kuo CC, Liu YM, et al: Hypoxia-Induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. Cancer Res. 77:4305–4316. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lin SC, Hsiao KY, Chang N, Hou PC and Tsai SJ: Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer. J Pathol. 241:638–648. 2017. View Article : Google Scholar : PubMed/NCBI
12	Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG and Reich R: The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol. 93:517–523. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhu W, Huang L, Xu X, Qian H and Xu W: Anti-proliferation effect of BMI-1 in U937 cells with siRNA. Int J Mol Med. 25:889–895. 2010.PubMed/NCBI
14	Wang XF, Zhao YB, Wu Q, Sun ZH and Li HJ: Triptolide induces apoptosis in endometrial cancer via a p53 independent mitochondrial pathway. Mol Med Rep. 9:39–44. 2014. View Article : Google Scholar : PubMed/NCBI
15	Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J and Berra E: HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer. 120:1451–1458. 2007. View Article : Google Scholar : PubMed/NCBI
16	Tashiro E, Henmi S, Odake H, Ino S and Imoto M: Involvement of the MEK/ERK pathway in EGF-induced E-cadherin down-regulation. Biochem Biophys Res Commun. 477:801–806. 2016. View Article : Google Scholar : PubMed/NCBI
17	Boeckx C, Op de Beeck K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P, Vermorken JB, Peeters M, et al: Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. Cancer Lett. 354:365–377. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chen Y, Huang Y, Hou P, Zhang Z, Zhang Y, Wang W, Sun G, Xu L, Zhou J, Bai J and Zheng J: ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer. Oncotarget. 7:79017–79031. 2016.PubMed/NCBI
19	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Song Y, Song N, Zhang Y, Zhang L, Wang Y, Wang Z, Qu X and Liu Y: RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src. Onco Targets Ther. 10:73–83. 2017. View Article : Google Scholar : PubMed/NCBI
21	Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, et al: Adjuvant FOLFOX +/−cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Ann Oncol. 28:824–830. 2017.PubMed/NCBI
22	Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R and Menendez JA: Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget. 7:82185–82199. 2016. View Article : Google Scholar : PubMed/NCBI
23	Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, Luo HY, Zhang DS, Jin Y, Wang FH, et al: Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 34:384–393. 2015. View Article : Google Scholar : PubMed/NCBI
24	Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, et al: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 51:1405–1414. 2015. View Article : Google Scholar : PubMed/NCBI
25	Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, et al: Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 21:988–994. 2016. View Article : Google Scholar : PubMed/NCBI
26	Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev. 17:79–92. 2017. View Article : Google Scholar
27	Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng L and Pei HP: Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis. Oncol Lett. 6:353–358. 2013. View Article : Google Scholar : PubMed/NCBI
28	Joo D, Woo JS, Cho KH, Han SH, Min TS, Yang DC and Yun CH: Biphasic activation of extracellular signal-regulated kinase (ERK)1/2 in epidermal growth factor (EGF)-stimulated SW480 colorectal cancer cells. BMB Rep. 49:220–225. 2016. View Article : Google Scholar : PubMed/NCBI